NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) 10-Year Financial Performance & Capital Metrics

NTHI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.Show more

Revenue $83K +17.8%
EBITDA -$7M +43.5%
Net Income -$12M +20.3%
EPS (Diluted) -0.63 +21.3%
Gross Margin 100%
EBITDA Margin -8309.13% +52.0%
Operating Margin -8605.45% +50.3%
Net Margin -14335.5% +32.3%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -2.64 +41.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM39.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-266.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-282.34%

ROCE

10Y Avg-

5Y Avg-

3Y Avg-

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	20K	70.46K	83K
Revenue Growth %	-	-	2.52%	0.18%
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	20K	70.46K	83K
Gross Margin %	-	1%	1%	1%
Gross Profit Growth %	-	-	2.52%	0.18%
Operating Expenses+	3.27M	2.86M	12.27M	7.23M
OpEx % of Revenue	-	142.88%	174.11%	87.05%
Selling, General & Admin	2.6M	1.69M	3.4M	3.64M
SG&A % of Revenue	-	84.71%	48.2%	43.84%
Research & Development	674.56K	1.16M	1.53M	3.05M
R&D % of Revenue	-	58.17%	21.77%	36.69%
Other Operating Expenses	0	0	7.34M	541.25K
Operating Income+	-3.27M	-2.84M	-12.2M	-7.14M
Operating Margin %	-	-141.88%	-173.11%	-86.05%
Operating Income Growth %	-	0.13%	-3.3%	0.41%
EBITDA+	-3.26M	-2.85M	-12.2M	-6.9M
EBITDA Margin %	-	-142.33%	-173.11%	-83.09%
EBITDA Growth %	-	0.13%	-3.28%	0.43%
D&A (Non-Cash Add-back)	0	0	0	245.94K
EBIT	-3.26M	-2.85M	-12.2M	-9.34M
Net Interest Income+	-112.92K	-200.15K	-2.72M	-2.69M
Interest Income	0	0	0	16.13K
Interest Expense	112.92K	200.15K	2.72M	2.7M
Other Income/Expense	-103.92K	-209.15K	-2.72M	-4.76M
Pretax Income+	-3.38M	-3.05M	-14.92M	-11.9M
Pretax Margin %	-	-152.34%	-211.76%	-143.35%
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-3.38M	-3.05M	-14.92M	-11.9M
Net Margin %	-	-152.34%	-211.76%	-143.35%
Net Income Growth %	-	0.1%	-3.9%	0.2%
Net Income (Continuing)	-3.38M	-3.05M	-14.92M	-11.9M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.18	-0.16	-0.80	-0.63
EPS Growth %	-	0.11%	-4%	0.21%
EPS (Basic)	-0.18	-0.16	-0.80	-0.63
Diluted Shares Outstanding	18.75M	18.75M	18.75M	18.75M
Basic Shares Outstanding	18.75M	18.75M	18.75M	18.75M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	32.49K	728.68K	1.27M	2.2M
Cash & Short-Term Investments	25.03K	633.3K	31.86K	64.89K
Cash Only	25.03K	633.3K	31.86K	64.89K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	148.71K
Days Sales Outstanding	-	-	-	653.94
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	970.58K	1.6M
Total Non-Current Assets+	0	0	0	1.22M
Property, Plant & Equipment	0	0	0	23.53K
Fixed Asset Turnover	-	-	-	3.53x
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	1.2M
Total Assets+	32.49K	728.68K	1.27M	3.42M
Asset Turnover	-	0.03x	0.06x	0.02x
Asset Growth %	-	21.43%	0.74%	1.7%
Total Current Liabilities+	2.65M	2.3M	15.25M	8.92M
Accounts Payable	537.45K	1.34M	2.96M	3.52M
Days Payables Outstanding	-	-	-	-
Short-Term Debt	1.15M	50K	6.61M	24.72K
Deferred Revenue (Current)	500K	500K	0	0
Other Current Liabilities	462.5K	0	1.09M	710.15K
Current Ratio	0.01x	0.32x	0.08x	0.25x
Quick Ratio	0.01x	0.32x	0.08x	0.25x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	0	-5K
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	-5K
Total Liabilities	2.65M	2.3M	15.25M	8.92M
Total Debt+	1.15M	50K	6.61M	24.72K
Net Debt	1.12M	-583.3K	6.57M	-40.17K
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-28.97x	-14.18x	-4.48x	-2.64x
Total Equity+	-2.62M	-1.58M	-13.99M	-5.5M
Equity Growth %	-	0.4%	-7.88%	0.61%
Book Value per Share	-0.14	-0.08	-0.75	-0.29
Total Shareholders' Equity	-2.62M	-1.58M	-13.99M	-5.5M
Common Stock	56.67K	1.05K	1.66K	1.81K
Retained Earnings	-20.74M	-23.79M	-38.71M	-50.61M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-396.69K	-881.74K	-1.88M	-4.21M
Operating CF Margin %	-	-44.09%	-26.68%	-50.77%
Operating CF Growth %	-	-1.22%	-1.13%	-1.24%
Net Income	-3.38M	-3.05M	-14.92M	-11.9M
Depreciation & Amortization	0	0	0	245.94K
Stock-Based Compensation	2.22M	1.29M	0	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	103.92K	206.89K	11.33M	5.95M
Working Capital Changes	655.66K	666.22K	1.71M	1.49M
Change in Receivables	82.75K	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	423.17K	804.15K	1.06M	1.8M
Cash from Investing+	0	0	0	0
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	0%	-	0%
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	250K	1.49M	1.28M	4.25M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	-700K	-94.57K	-469.79K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-396.69K	-881.74K	-1.88M	-4.21M
FCF Margin %	-	-44.09%	-26.68%	-50.77%
FCF Growth %	-	-1.22%	-1.13%	-1.24%
FCF per Share	-0.02	-0.05	-0.10	-0.22
FCF Conversion (FCF/Net Income)	0.12x	0.29x	0.13x	0.35x
Interest Paid	0	2.26K	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Gross Margin	-	100%	100%	100%
Net Margin	-	-15233.78%	-21176.05%	-14335.5%
Interest Coverage	-28.97x	-14.18x	-4.48x	-2.64x
FCF Conversion	0.12x	0.29x	0.13x	0.35x
Revenue Growth	-	-	252.31%	17.79%

Frequently Asked Questions

Growth & Financials

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported $0.1M in revenue for fiscal year 2024.

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) grew revenue by 17.8% over the past year. This is strong growth.

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported a net loss of $54.6M for fiscal year 2024.

Dividend & Returns

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) had negative free cash flow of $17.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener